PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Omega Ophthalmics Llc

USPTO PatentsView assignee record — 41 granted patents across 2 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).

Explore the portfolio See the ranking
41
Total patents granted
2
CPC technology areas
19.1
Avg claims per patent
+28%
5-year filing velocity

The verdict

Omega holds 41 US patents across 2 technology areas — rank #7,903 of 50,000 tracked assignees.

#7,903
of 50,000 US assignees by volume
Top 46%
by Innovation Score (36.6/100)
19.1
avg claims per patent
+28%
filing velocity, last 5 yrs

Portfolio overview

Omega Ophthalmics LLC has been granted 41 US utility patents between 2016 and 2025, placing Omega Ophthalmics LLC at rank #7,903 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.1 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, Omega Ophthalmics LLC is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 36.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 23 grants, compared with 18 in the 2015–2019 window — a +28% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Omega Ophthalmics LLC's 19.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Omega Ophthalmics LLC against peers pursuing similar technology classes.

How does Omega compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Omega holds 41 patents — placing it at rank #7,903 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Omega's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

37 Top 46% higher than 54% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

02468 2016201720182019202020212022202320242025 2
USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Omega Ophthalmics LLC patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 7 17.1%
2017 4 9.8%
2018 5 12.2%
2019 2 4.9%
2020 5 12.2%
2021 4 9.8%
2022 4 9.8%
2023 5 12.2%
2024 3 7.3%
2025 2 4.9%

Which technologies does Omega Ophthalmics LLC patent most?

Top 2 of 2 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Growing

Where it ranks

Overall rank by patents

#7,903

Across all tracked assignees

Innovation Score

36.6 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Omega Ophthalmics LLC hold?
Omega Ophthalmics LLC holds 41 US granted patents filed between 2016 and 2025, spanning 2 technology areas.
What is Omega Ophthalmics LLC's Innovation Score?
Omega Ophthalmics LLC has an Innovation Score of 36.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Omega Ophthalmics LLC focus on?
Omega Ophthalmics LLC's top technology area is A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS) with 41 patents. The company has filed patents in 2 CPC subclasses total.
Is Omega Ophthalmics LLC's patent filing rate increasing or decreasing?
Omega Ophthalmics LLC's recent filing velocity is +28% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Omega Ophthalmics LLC's patents?
Omega Ophthalmics LLC's patents average 19.1 claims each. This falls within the standard range, providing solid legal coverage.
How is the Omega Ophthalmics LLC patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

How to use this portfolio

Omega's 41 grants land it in the top 46% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Omega ranks #7,903 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61F — see who else leads that technology area. A61F leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

A61F technology

Omega Ophthalmics LLC's primary CPC class — all holders and yearly trends
Top 50 patent holders

See where Omega Ophthalmics LLC ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology — how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov